Phaseline

Companies › Curis

Curis: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Emavusertib (CA-4948)–Phase 2Chronic Lymphocytic Leukemia; Relapsed Hematologic Malignancy; Metastatic Colorectal Adenocarcinoma; Metastatic Urothelial Carcinoma …Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06696768Emavusertib (CA-4948)Phase 1Metastatic Colorectal AdenocarcinomaOncologyDec 2026
NCT06439836Emavusertib (CA-4948)Phase 1Metastatic Urothelial CarcinomaOncologyJun 2027
NCT03328078Emavusertib (CA-4948)Phase 1Relapsed Hematologic MalignancyOncologyJul 2027
NCT07271667Emavusertib (CA-4948)Phase 2Chronic Lymphocytic LeukemiaOncologyNov 2027
NCT05187182Emavusertib (CA-4948)Phase 1Gastric CancerOncologyJul 2028
NCT07107750Emavusertib (CA-4948)Phase 1Metastatic Biliary Tract CancerOncologyJun 2030

From the company's SEC filings

Cash and short-term investments of $5m on 2026-06-30; operating cash outflow about $38m a year; runway about 2 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dogwood Therapeutics Atossa Therapeutics Processa Pharmaceuticals Moleculin Biotech Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.